» Articles » PMID: 16903919

Regulatory T Cells Suppress Systemic and Mucosal Immune Activation to Control Intestinal Inflammation

Overview
Journal Immunol Rev
Date 2006 Aug 15
PMID 16903919
Citations 215
Authors
Affiliations
Soon will be listed here.
Abstract

The gastrointestinal (GI) tract is the main interface where the body encounters exogenous antigens. It is crucial that the local response here is tightly regulated to avoid an immune reaction against dietary antigens and commensal flora while still mounting an efficient defense against pathogens. Faults in establishing intestinal tolerance can lead to disease, inducing local and often also systemic inflammation. Studies in human as well as in animal models suggest a role for regulatory T cells (Tregs) in maintaining intestinal homeostasis. Transfer of Tregs can not only prevent the development of colitis in animal models but also cure established disease, acting both systemically and at the site of inflammation. In this review, we discuss the major regulatory pathways, including transforming growth factor-beta (TGF-beta), interleukin-10 (IL-10), and cytotoxic T-lymphocyte antigen-4 (CTLA-4), and their role in Treg-mediated control of systemic and mucosal responses. In addition, we give an overview of the known mechanisms of lymphocyte migration to the intestine and discuss how CD103 expression can influence the balance between regulatory and effector T cells. Further understanding of the factors that control the activity of Tregs in different immune compartments may facilitate the design of strategies to target regulation in a tissue-specific way.

Citing Articles

Prenatal Stress and Ethanol Exposure: Microbiota-Induced Immune Dysregulation and Psychiatric Risks.

Camarini R, Marianno P, Hanampa-Maquera M, Oliveira S, Camara N Int J Mol Sci. 2024; 25(18).

PMID: 39337263 PMC: 11431796. DOI: 10.3390/ijms25189776.


Solute Transporter OCTN1/Slc22a4 Affects Disease Severity and Response to Infliximab in Experimental Colitis: Role of Gut Microbiota and Immune Modulation.

Del Chierico F, Masi L, Petito V, Baldelli V, Puca P, Benvenuto R Inflamm Bowel Dis. 2024; 30(12):2259-2270.

PMID: 38944815 PMC: 11630256. DOI: 10.1093/ibd/izae135.


Novel 5-HT receptor antagonists modulate intestinal immune responses and reduce severity of colitis.

Kwon Y, Blass B, Wang H, Grondin J, Banskota S, Korzekwa K Am J Physiol Gastrointest Liver Physiol. 2024; 327(1):G57-G69.

PMID: 38713616 PMC: 11550998. DOI: 10.1152/ajpgi.00299.2023.


in Inflammatory Bowel Diseases: Active Protagonist or Innocent Bystander?.

Bretto E, Frara S, Armandi A, Caviglia G, Saracco G, Bugianesi E Antibiotics (Basel). 2024; 13(3).

PMID: 38534702 PMC: 10967592. DOI: 10.3390/antibiotics13030267.


Ring1a protects against colitis through regulating mucosal immune system and colonic microbial ecology.

Wang Y, Li Q, Zhang J, Liu P, Zheng H, Chen L Gut Microbes. 2023; 15(2):2251646.

PMID: 37655448 PMC: 10478745. DOI: 10.1080/19490976.2023.2251646.